Clinical trial
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary…
NCT00277160 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00277160 |
|---|---|
| Title | A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer |
| Official title | A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Neutropenia, Breast Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Neulasta (pegfilgrastim) |
| Enrollment | 852 |
| Start date | Jun 1, 2002 |
| Primary completion | Nov 1, 2004 |
| Completion | Jan 1, 2005 |
| First posted | Jan 16, 2006 |
| Last update posted | Oct 8, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: